Cryoport shares slide 29% after revenue warning
Shares of Cryoport Inc. (CYRX) fell 29% in premarket trading on Thursday after the life-science logistics company issued a revenue warning, noting weaker than expected global demand for capital equipment and clinical trial start delays. Cryoport expects second quarter revenue to be in the range of $56.5 million to $57.5 million, down 11% at the midpoint from the same period a year earlier, the company said in a release late Wednesday. Several key customers are falling short of expected revenues from certain cell and gene therapies, the company said, and the challenging conditions are expected to persist in the third and fourth quarter. Full-year 2023 revenue is now expected to be in the range of $233 million to $243 million, down from previous guidance of $270 million to $290 million.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-13-23 0808ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters